Ind-Swift Laboratories (NSEI:INDSWFTLAB) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

INDSWFTLAB Overzicht aandelen

INDSWFTLAB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Price-To-Earnings ratio (1.9x) is below the Indian market (34.3x)

Earnings grew by 800% over the past year

Risicoanalyse

Significant insider selling over the past 3 months

Large one-off items impacting financial results

Does not have a meaningful market cap (₹8B)

Volatile share price over the past 3 months

Ind-Swift Laboratories Limited Concurrenten

Albert David

BSE:524075

₹8.5b

Wanbury

BSE:524212

₹8.6b

Sakar Healthcare

NSEI:SAKAR

₹6.8b

Nectar Lifesciences

NSEI:NECLIFE

₹9.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ind-Swift Laboratories
Historische aandelenkoersen
Huidige aandelenkoers	₹128.60
52 Week Hoogtepunt	₹186.00
52 Week Laag	₹81.85
Bèta	0.23
11 maand verandering	-13.52%
3 maanden verandering	-3.61%
1 Jaar Verandering	40.39%
33 jaar verandering	103.48%
5 jaar verandering	213.66%
Verandering sinds IPO	616.43%

Recent nieuws en updates

Recent updates

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Jul 02

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27

Rendement voor aandeelhouders

	INDSWFTLAB	IN Pharmaceuticals	IN Markt
7D	-2.2%	0.2%	-0.3%
1Y	40.4%	59.4%	44.6%

Rendement versus industrie: INDSWFTLAB underperformed the Indian Pharmaceuticals industry which returned 58.2% over the past year.

Rendement versus markt: INDSWFTLAB underperformed the Indian Market which returned 44.2% over the past year.

Prijsvolatiliteit

Is INDSWFTLAB's price volatile compared to industry and market?
INDSWFTLAB volatility
INDSWFTLAB Average Weekly Movement	9.2%
Pharmaceuticals Industry Average Movement	6.2%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	3.9%

Stabiele aandelenkoers: INDSWFTLAB's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: INDSWFTLAB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	47	Navrattan Munjal	www.indswiftlabs.com

Ind-Swift Laboratories Limited ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen actieve farmaceutische ingrediënten (API's), tussenproducten en formuleringen in India en daarbuiten. Het bedrijf biedt API's voor verschillende therapeutische gebieden, waaronder macrolide antibiotica, cardiovasculaire middelen, antihistaminica, antidiabetica, antipsychotica, botresorptieremmers, de ziekte van Parkinson, hyperparathyrodisme, pijnstillers, aromataseremmers, nootropica, antidiarree/antiprotozoa, alcoholonthouding, antineoplastica, ADHD-symptomen, antikanker, hypercholesterolemie, antimigraine en trombocytopenie. Het biedt ook referentiestandaarden en onzuiverheden voor acamprosaatcalcium, anastrozol, aripiprazol, atorvastatinecalcium, azitromycinedihydraat, bexaroteen, cinacalcethydrochloride, clopidogrel bisulfaat, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylaat, ivabradine hydrochloride, ivabradine oxalaat, letrozol, mecloxamine citraat, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumaraat, raltegravir kalium, ropinirole hydrochloride, rosuvastatine calcium, saxagliptine monohydraat, silodosine en temozolomide, evenals contractonderzoek en productiediensten.

Ind-Swift Laboratories Limited Samenvatting

Hoe verhouden de winst en inkomsten van Ind-Swift Laboratories zich tot de beurswaarde?
INDSWFTLAB fundamentele statistieken
Marktkapitalisatie	₹7.60b
Inkomsten(TTM)	₹4.05b
Inkomsten(TTM)	₹10.04b

1.9x

Koers/Winstverhouding

0.8x

P/S-verhouding

Is INDSWFTLAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
INDSWFTLAB resultatenrekening (TTM)
Inkomsten	₹10.04b
Kosten van inkomsten	₹5.27b
Brutowinst	₹4.77b
Overige uitgaven	₹725.60m
Inkomsten	₹4.05b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 14, 2024

Winst per aandeel (EPS)	68.48
Brutomarge	47.54%
Nettowinstmarge	40.32%
Schuld/Eigen Vermogen Verhouding	1.8%

Hoe presteerde INDSWFTLAB op de lange termijn?

Bekijk historische prestaties en vergelijking

INDSWFTLAB Overzicht aandelen

Beloningen

Risicoanalyse

Ind-Swift Laboratories Limited Concurrenten

BSE:524075

₹8.5b

BSE:524212

₹8.6b

NSEI:SAKAR

₹6.8b

NSEI:NECLIFE

₹9.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

Investor sentiment deteriorates as stock falls 21%

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Recent updates

Chief Financial Officer recently sold ₹4.2m worth of stock

Ind-Swift Laboratories Limited to Report Q3, 2025 Results on Feb 14, 2025

Investor sentiment deteriorates as stock falls 21%

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹2.92 in 1Q 2024)

Ind-Swift Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024

Investor sentiment improves as stock rises 24%

Ind-Swift Laboratories Limited Appoints Mr. Param Bir Singh as an Independent Director

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

New minor risk - Share price stability

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Full year 2024 earnings released: EPS: ₹71.24 (vs ₹8.06 in FY 2023)

New minor risk - Share price stability

Ind-Swift Laboratories Limited to Report Q4, 2024 Results on May 13, 2024

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 15%

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Essix Biosciences Limited.

Third quarter 2024 earnings released: EPS: ₹3.29 (vs ₹4.65 in 3Q 2023)

Ind-Swift Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Second quarter 2024 earnings released: EPS: ₹5.36 (vs ₹4.29 in 2Q 2023)

Ind-Swift Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: ₹2.92 (vs ₹3.36 in 1Q 2023)

Ind-Swift Laboratories Limited to Report Q1, 2024 Results on Aug 09, 2023

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Group Head of Human Resources recently sold ₹3.3m worth of stock

Investor sentiment improves as stock rises 16%

Chief Accounts Officer recently sold ₹1.6m worth of stock

Full year 2023 earnings released: EPS: ₹8.06 (vs ₹0.36 loss in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: ₹4.65 (vs ₹2.71 in 3Q 2022)

Insider recently sold ₹1.2m worth of stock

Second quarter 2023 earnings released: EPS: ₹4.29 (vs ₹4.14 in 2Q 2022)

Insider recently sold ₹1.6m worth of stock

Ind-Swift Laboratories Limited to Report Fiscal Year 2023 Results on May 30, 2023

First quarter 2023 earnings released: EPS: ₹3.36 (vs ₹3.18 in 1Q 2022)

Ind-Swift Laboratories Limited, Annual General Meeting, Sep 30, 2022

Ind-Swift Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings released: ₹0.36 loss per share (vs ₹0.53 loss in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹4.14 (vs ₹1.68 in 2Q 2021)

Investor sentiment deteriorated over the past week

Soft Air General Trading LLC agreed to acquire Ind-Swift Middle East FZ-LLC from Ind-Swift Laboratories Limited (BSE:532305) for approximately $2 million.

First quarter 2022 earnings released: EPS ₹3.18 (vs ₹0.77 in 1Q 2021)

High number of new directors

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Full year 2021 earnings released: ₹0.53 loss per share (vs ₹4.28 loss in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insider recently sold ₹1.0m worth of stock